Erasca (ERAS) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 469.4% versus a gain of 11.7%. Over five years, MIRM leads with a +371.0% price change compared with -20.7% for ERAS. Erasca is the larger company by market cap ($5.41 billion vs $5.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | MIRM |
|---|---|---|
| Share price | $15.46 | $81.35 |
| Market cap | $5.41B | $5.28B |
| 1-day change | +9.49% | +0.88% |
| YTD return | +279.57% | +2.99% |
| 1-year return | +469.35% | +11.67% |
| 5-year return | -20.67% | +371.03% |
| EPS (TTM) | $-0.95 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | $-124.55M | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $24.28 | $130.00 |
| 52-week low | $2.11 | $63.23 |
| Distance from 52-week high | -36.33% | -37.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.95% | +79.21% |
| Average volume | 4.28M | 698.74K |
| Shares outstanding | 349.76M | 64.93M |
| Employees | 103 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed MIRM by 457.7 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
ERAS vs MIRM FAQ
Which is bigger, Erasca or Mirum Pharmaceuticals?
Erasca (ERAS) is larger, with a market capitalization of $5.41B compared with $5.28B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, ERAS or MIRM?
ERAS returned +469.35% over the past 12 months, compared with +11.67% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.